	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	9,709	11,896	13,415	15,023	15,568	14,196	14,281	15,448	17,517	19,048	21,545	24,670	28,011	32,644	33,700
Cost of Operating Revenue	3,487	4,527	4,847	5,162	5,393	5,235	5,598	6,114	7,176	7,794	9,162	9,555	10,410	12,487	15,095
Gross Profit	6,222	7,368	8,569	9,861	10,175	8,961	8,684	9,334	10,341	11,254	12,383	15,115	17,601	20,157	18,605
Gross Margin	64.1	61.9	63.9	65.6	65.4	63.1	60.8	60.4	59.0	59.1	57.5	61.3	62.8	61.7	55.2
Total Operating Expenses	7,898	9,723	10,812	12,275	12,482	12,666	13,007	13,393	14,526	15,725	18,012	19,380	21,548	25,631	28,954
Operating Profit	1,811	2,173	2,603	2,748	3,086	1,530	1,274	2,055	2,991	3,322	3,533	5,290	6,463	7,013	4,747
Operating Margin	18.7	18.3	19.4	18.3	19.8	10.8	8.9	13.3	17.1	17.4	16.4	21.4	23.1	21.5	14.1
Financing Income/(Expense) - Net	24	44	39	164	-309	30	61	81	53	110	184	196	84	117	175
Profit before Taxes	1,804	2,165	2,646	2,900	2,859	1,554	1,350	2,292	1,830	2,836	2,991	6,012	7,186	7,658	5,379
Income Taxes	504	638	683	563	751	297	311	386	-136	963	883	1,541	1,623	1,954	1,235
Profit after Tax	1,301	1,527	1,963	2,336	2,131	1,292	947	1,950	2,026	1,952	2,183	4,507	5,578	5,655	4,196
PAT Margin	13.4	12.8	14.6	15.6	13.7	9.1	6.6	12.6	11.6	10.2	10.1	18.3	19.9	17.3	12.5
EPS - Basic - ex Extraordinary Items	15.35	17.99	23.09	27.44	24.99	15.51	12.95	23.51	24.40	23.16	26.26	54.29	67.04	67.89	50.41
EPS - Diluted - ex Extraordinary Items	15.27	17.90	22.98	27.32	24.91	15.47	12.92	23.47	24.35	23.09	26.19	54.18	66.92	67.79	50.35
EBIT	1,811	2,173	2,603	2,748	3,086	1,530	1,274	2,055	2,991	3,322	3,533	5,290	6,463	7,013	4,747
EBITDA	2,329	2,723	3,251	3,508	4,016	2,557	2,351	3,190	4,154	4,551	4,698	6,540	7,933	8,716	6,805
EBITDA Margin	24.0	22.9	24.2	23.4	25.8	18.0	16.5	20.6	23.7	23.9	21.8	26.5	28.3	26.7	20.2

Balance Sheet

Abridged

Understanding Balance Sheet

Dr. Reddys Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	6,999	8,527	10,326	11,810	11,794	9,684	10,498	11,110	12,599	14,550	17,782	20,426	24,805	25,018	30,179
Long-Term Investments	1	0	0	287	215	537	264	98	51	506	377	72	152	1,052	1,096
Property Plant & Equipment - Net	3,282	3,707	4,388	4,695	5,276	5,638	5,741	5,385	5,214	5,686	6,167	6,629	7,600	9,698	11,538
Total Non-Current Assets	4,325	4,961	5,704	7,255	8,590	12,133	12,046	11,356	10,626	12,067	11,965	11,860	14,059	24,409	27,944
Total Assets	11,324	13,487	16,030	19,065	20,384	21,817	22,544	22,466	23,225	26,617	29,747	32,285	38,864	49,427	58,123
Total Current Liabilities	4,591	5,659	5,790	6,373	6,347	8,420	6,894	5,897	7,214	8,104	9,766	8,572	9,588	13,034	16,747
Long Term Debt	1,642	1,266	2,076	1,431	1,069	545	2,509	2,200	130	630	575	128	599	786	1,220
Total Non-Current Liabilities	1,744	1,459	2,374	1,858	1,467	1,135	3,079	2,545	412	871	769	427	1,021	2,465	3,145
Total Liabilities	6,335	7,118	8,164	8,232	7,814	9,554	9,973	8,442	7,627	8,975	10,535	8,999	10,609	15,499	19,893
Total Shareholders' Equity	4,989	6,369	7,865	10,833	12,570	12,262	12,572	14,024	15,599	17,642	19,212	23,286	28,255	33,550	37,892
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	378	339
Total Equity	4,989	6,369	7,865	10,833	12,570	12,262	12,572	14,024	15,599	17,642	19,212	23,286	28,255	33,927	38,231
Total Liabilities & Equity	11,324	13,487	16,030	19,065	20,384	21,817	22,544	22,466	23,225	26,617	29,747	32,285	38,864	49,427	58,123

Cash Flow

Abridged

Understanding Cash Flow Statement

Dr. Reddys Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	2,429	2,631	2,955	3,979	3,302	2,640	2,594	2,604	3,679	4,389	4,146	6,565	6,469	7,631	6,456
Working Capital - Increase/(Decrease)	-894	-1,294	-1,005	-1,484	-3	-525	-897	184	-754	-829	-1,382	-786	-2,018	-2,999	-1,075
Net CF from Operating Activities	1,535	1,337	1,950	2,496	3,299	2,115	1,697	2,788	2,925	3,560	2,764	5,780	4,451	4,632	5,382
Capital Expenditures - Net	863	751	1,075	1,514	1,473	4,089	1,090	623	573	1,248	1,573	1,878	2,635	3,315	3,670
Net CF from Investing Activities	-1,922	-1,531	-1,791	-2,346	-2,168	-1,903	-1,516	-851	-594	-2,388	-2,726	-4,215	-4,162	-6,145	-6,701
Dividends Paid - Cash - Total	222	272	298	359	411	339	399	400	392	415	415	498	665	666	666
Stock - Issuance/(Retirement) - Net	1	0	0	1	0	-1,569	0	-54	-47	-92	33	37	81	-120	40
Debt - LT & ST - Issuance/(Retirement) - Total	721	240	390	34	-1,198	1,631	88	-1,518	-1,917	609	274	-2,040	435	2,320	1,899
Net Cash Flow from Financing Activities	500	-31	92	-324	-1,609	-277	-311	-1,972	-2,355	102	-108	-2,501	-150	2,239	1,273
Free Cash Flow to Equity	1,393	827	1,265	1,015	628	-342	695	647	436	2,922	1,464	1,862	2,250	3,636	3,612
Free Operating CF net dividend	432	310	569	605	1,407	-2,317	194	1,550	1,922	1,889	444	3,395	1,042	526	875
Free Operating CF	653	581	867	964	1,818	-1,978	593	1,950	2,313	2,304	859	3,893	1,707	1,192	1,541

Business Segment Analysis

FY End:

Mar 26

Dr. Reddys Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Revenue / Sales

Pharmaceutical Services and Active Ingredients (87.0%)₹ 29,946.00 CrGlobal Generics (12.4%)₹ 4,267.20 CrOther (0.6%)₹ 214.00 Cr

Regional Segment Analysis

FY End:

Mar 26

Dr. Reddys Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Other (26.1%)₹ 11,871.80 CrOthers (26.1%)₹ 11,871.80 CrUnited States (25.9%)₹ 11,789.20 CrIndia (14.2%)₹ 6,453.70 CrRussia (7.7%)₹ 3,478.60 Cr

Historical Segment Analysis

Track how Dr. Reddys Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Sales

Assets

Operating Income

Business

Regional

Business

We don't have enough data to show the Capex for Dr. Reddys Laboratories Ltd..

Frequently Asked Questions

What is the revenue of Dr. Reddys Laboratories Ltd.?

The latest trailing twelve month revenue of Dr. Reddys Laboratories Ltd. is ₹ 33,700.20 Cr, reflecting a 1-year growth of 3.24% and a 3-year CAGR of 10.96%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Dr. Reddys Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Dr. Reddys Laboratories Ltd. is ₹ 4,196.00 Cr, with a 3-year earnings CAGR of -2.41%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Dr. Reddys Laboratories Ltd.?

The trailing twelve month EBITDA of Dr. Reddys Laboratories Ltd. is approximately ₹ 4,876.39 Cr (based on an operating margin of 14.47%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Dr. Reddys Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Dr. Reddys Laboratories Ltd. is 50.35. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Dr. Reddys Laboratories Ltd.?

The debt-to-equity ratio of Dr. Reddys Laboratories Ltd. stands at 0.20. The interest coverage ratio is 13.05x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Dr. Reddys Laboratories Ltd.?

The estimated book value per share of Dr. Reddys Laboratories Ltd. is 466.87 (derived from a P/B ratio of 2.96 and market price of ₹ 1,380.70), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Dr. Reddys Laboratories Ltd.?

The trailing twelve month operating cash flow of Dr. Reddys Laboratories Ltd. is ₹ 5,381.70 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Dr. Reddys Laboratories Ltd. report consolidated or standalone financials?

Dr. Reddys Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.